Callan JMB Q2 revenue $1.7M, operating loss $1.4M; forms Revival partnership, secures $25M equity line

CALLAN JMB INC.

2025-Q2 EPS reported -$0.63 revenue$3,115,687

Q2 2025 revenue $1.7M, down YoY; H1 revenue $3.1M; gross profit $0.6M and $1.3M respectively.
Operating loss of $1.4M (Q2) and $2.6M (H1); SG&A rose to $2.0M in Q2 on public-company and hiring costs.
Cash $4.2M at June 30; post-quarter equity line for up to $25M of common stock.
Strategic partnership with Revival Health; launched Indian subsidiary with temperature-controlled warehouse.
Extended Chicago emergency contract to June 2026 with $1.5M increase, total $9.1M; appointed Christopher Shields as SVP.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.